Abstract
Spinal cord (SC) injury causes serious neurological alterations that importantly disturb the physical, emotional and economical stability of affected individuals. Damage to the neural tissue is primarily caused by the lesion itself and secondarily by a multitude of destructive mechanisms that develop afterwards. Unfortunately, the restoring capacity of the central nervous system is very limited because of reduced intrinsic growth capacity and non-permissive environment for axonal elongation. The regenerative processes are blocked by diverse factors such as growth inhibitory proteins and the glial scar formed in the site of lesion. In spite of these problems, central neurons regenerate if a permissive environment is provided. In line with this thought, some pharmacological compounds have been tested to achieve neuroregeneration. The main objective of this manuscript is to provide the state-of-art of chemotherapeutic treatments for spinal cord regeneration after injury in the field. The efficacy and usefulness of different therapeutic strategies will be reviewed, including Rho-ROCK inhibitors, cyclic AMPenhancers, glial scar inhibitors and immunophilin ligands. Aside from this, the use of hydrogels alone or in combination with drugs, growth factors or stem cells will also be revised.
Keywords: Cyclic AMP-enhancers, glial scar inhibitors, hydrogels, immunophilin ligands, paraplegia, regeneration, Rho pathway antagonists, spinal cord transection
Current Drug Discovery Technologies
Title: Pharmacological Approaches to Induce Neuroregeneration in Spinal Cord Injury: An Overview
Volume: 6 Issue: 2
Author(s): Susana Martinon and Antonio Ibarra
Affiliation:
Keywords: Cyclic AMP-enhancers, glial scar inhibitors, hydrogels, immunophilin ligands, paraplegia, regeneration, Rho pathway antagonists, spinal cord transection
Abstract: Spinal cord (SC) injury causes serious neurological alterations that importantly disturb the physical, emotional and economical stability of affected individuals. Damage to the neural tissue is primarily caused by the lesion itself and secondarily by a multitude of destructive mechanisms that develop afterwards. Unfortunately, the restoring capacity of the central nervous system is very limited because of reduced intrinsic growth capacity and non-permissive environment for axonal elongation. The regenerative processes are blocked by diverse factors such as growth inhibitory proteins and the glial scar formed in the site of lesion. In spite of these problems, central neurons regenerate if a permissive environment is provided. In line with this thought, some pharmacological compounds have been tested to achieve neuroregeneration. The main objective of this manuscript is to provide the state-of-art of chemotherapeutic treatments for spinal cord regeneration after injury in the field. The efficacy and usefulness of different therapeutic strategies will be reviewed, including Rho-ROCK inhibitors, cyclic AMPenhancers, glial scar inhibitors and immunophilin ligands. Aside from this, the use of hydrogels alone or in combination with drugs, growth factors or stem cells will also be revised.
Export Options
About this article
Cite this article as:
Martinon Susana and Ibarra Antonio, Pharmacological Approaches to Induce Neuroregeneration in Spinal Cord Injury: An Overview, Current Drug Discovery Technologies 2009; 6 (2) . https://dx.doi.org/10.2174/157016309788488320
DOI https://dx.doi.org/10.2174/157016309788488320 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Central Nervous System Agents in Medicinal Chemistry 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Immunotherapy Strategies for Spinal Cord Injury
Current Pharmaceutical Biotechnology Multilevel Analysis of Locomotion in Immature Preparations Suggests Innovative Strategies to Reactivate Stepping after Spinal Cord Injury
Current Pharmaceutical Design Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients
Current HIV Research Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Role of Immune Cells in the Course of Central Nervous System Injury: Modulation with Natural Products
Current Pharmaceutical Design Subretinal Transplantation of Rat MSCs and Erythropoietin Gene Modified Rat MSCs for Protecting and Rescuing Degenerative Retina in Rats
Current Molecular Medicine Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Current Molecular Medicine The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued)